Bimzelx® (bimekizumab-bkzx) injection for subcutaneous use
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Yuflyma™ (adalimumab-aaty) injection
Approval Date: May 2023
A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis
Idacio® (adalimumab-aacf) injection
Approval Date: Dec 2022
Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis
Tazorac® (tazarotene) gel
Approval Date: Sep 2022
Indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement
Sotyktu™ (deucravacitnib) tablets
Approval Date: Sep 2022
Indicated for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy
Zoryve™ (roflumilast) cream
Approval Date: Jul 2022
Indicated for topical treatment of plaque psoriasis
Vtama® (tapinarof) cream
Approval Date: May 2022
A steroid-free topical indicated for treatment of plaque psoriasis
Riabni™ (rituximab-arrx)
Approval Date: Jun 2022
A biosimilar to Rituxan® with existing oncology indications, this drug is now approved for the treatment of moderate-to-severe rheumatoid arthritis, in combination with methotrexate.
Skyrizi® (risankizumab-rzza) injection
Approval Date: Jun 2022
Approved for its third indication for moderately to severely active Crohn’s disease, in addition to existing indications for moderate-to-severe plaque psoriasis and active psoriatic arthritis.
Yusimry (adalimumab-aqvh) injection
Approval Date: Dec 2021
The 7th biosimilar approved for adalimumab. For the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis
